𝔖 Bobbio Scriptorium
✦   LIBER   ✦

Immune reconstitution in ADA-SCID after PBL gene therapy and discontinuation of enzyme replacement

✍ Scribed by Aiuti, Alessandro; Vai, Sergio; Mortellaro, Alessandra; Casorati, Giulia; Ficara, Francesca; Andolfi, Grazia; Ferrari, Giuliana; Tabucchi, Antonella; Carlucci, Filippo; Ochs, Hans D.

Book ID
109928226
Publisher
Nature Publishing Group
Year
2002
Tongue
English
Weight
115 KB
Volume
8
Category
Article
ISSN
1078-8956

No coin nor oath required. For personal study only.

πŸ“œ SIMILAR VOLUMES

Acute lymphoblastic leukemia in a patien
Acute lymphoblastic leukemia in a patient with type 1 Gaucher disease developing 1 year after discontinuation of enzyme replacement therapy
✍ Aditi Ranade; Sorin Selegean; Gagangeet Sandhu; Violette Ghali; Vijay P. Shah πŸ“‚ Article πŸ“… 2010 πŸ› John Wiley and Sons 🌐 English βš– 215 KB πŸ‘ 1 views

Higher rates of venous thromboembolism for Black-Americans are likely due to lower serum ## 25-hydroxyvitamin D levels To the editor: The recent paper on disparities of thromboembolism in the United States concluded that heritability may be important in the etiology of venous thromboembolism amon

Partial phenotypic correction and immune
Partial phenotypic correction and immune tolerance induction to enzyme replacement therapy after hematopoietic stem cell gene transfer of Ξ±-glucosidase in Pompe disease
✍ GaΓ«lle Douillard-Guilloux; Emmanuel Richard; Lionel Batista; Catherine Caillaud πŸ“‚ Article πŸ“… 2009 πŸ› John Wiley and Sons 🌐 English βš– 472 KB πŸ‘ 1 views

## Abstract ## Background Glycogen storage disease type II (GSDII) or Pompe disease is an inherited disease of glycogen metabolism caused by a lack of functional lysosomal acid α‐glucosidase (GAA). Affected individuals store glycogen in lysosomes resulting in fatal hypertrophic cardiomyopathy and